# Problem Statement

## Background

[Clinical trials are conducted under strict protocols defined during trial design, specifying eligibility criteria, dosing schedules, visit windows, and monitoring requirements. These trials generate continuous streams of patient-level data (visit records, lab results, dosing logs, adverse event reports) that must be checked against the approved protocol throughout the trial's duration. Regulatory bodies (FDA, EMA) require sponsors to follow ICH E6 Good Clinical Practice (GCP) guidelines, which classify any divergence from protocol as a "protocol deviation" that must be documented, assessed for severity, and — where significant — corrected through a formal Corrective and Preventive Action (CAPA) process.]

## The Problem

[Clinical Research Associates (CRAs) and trial site monitors currently review protocol adherence manually, cross-referencing patient records against protocol specifications on a case-by-case basis, often during periodic (monthly or quarterly) site visits rather than continuously. Deviations often go undetected for weeks between monitoring visits, and severity classification is inconsistent because it depends on the reviewer's individual judgment rather than a standardized framework. Sites with recurring, related deviations are not flagged as "high-risk" in real time, so an emerging pattern of protocol drift at a given site may only surface after significant damage — to data integrity, patient safety, or regulatory standing — has already occurred.]

## Who is Affected

[Clinical Research Associates and clinical trial monitors at contract research organizations (CROs) and pharmaceutical sponsors, who are each typically responsible for overseeing multiple trial sites and must manually audit patient-level compliance against a written protocol document. Also affected are trial site coordinators, who must react to deviations after the fact rather than catching them early, and regulatory/quality teams who must compile CAPA reports for audits and submissions.]
## Why It Matters

[Undetected or late-caught protocol deviations can compromise data integrity, jeopardize regulatory approval, and in serious cases put patient safety at risk. Regulatory findings tied to deviations can delay drug approval timelines by months, and each day of trial delay carries substantial cost to sponsors. Manual review also consumes significant CRA time that could otherwise go toward higher-value site support, and inconsistent severity classification increases the risk of both under-reporting (missed safety signals) and over-reporting (audit fatigue, resource waste).]

## Why Existing Solutions Fall Short

[Most sites rely on manual chart review, spreadsheet-based tracking, or periodic monitoring visits rather than automated, continuous surveillance. Existing eClinical/EDC (electronic data capture) systems capture patient data but generally don't natively compare it against protocol logic to auto-classify deviations by ICH E6 GCP severity, nor do they aggregate deviations into a site-level risk score that would let sponsors prioritize monitoring resources. Where automated checks do exist, they tend to be rigid rule-based validators built for one trial's protocol rather than a flexible tool that can classify severity, generate CAPA-ready mitigation reports, and surface risk patterns across an entire site — which is the gap your P1 tool is meant to fill.]
